Given the promising preclinical characterisation of [177Lu]Lu-DOTA-C595 in PDAC, future research should consider applying [177Lu]Lu-DOTA-C595 to other epithelial malignancies with MUC1-CE overexpression such as lung, colon and ovarian adenocarcinoma. This evidence concerns the gene MUC1 and ovarian adenocarcinoma.